News Postdoctoral fellowship at the University of Pennsylvania Research Fellow position, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milan, Italy. Laboratory Head, The Division of Cell- and Gene Therapy, University of Zurich Reviews and articles invited for "Advances in Gene and Cell Therapy" Special Issue In memory of Dr. Manfred Schmidt (Associate / Senior) Director, Immunology of Virus-Host Interactions, Vector BioPharma AG, Basel Review article: Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI) ERC Horizon Europe 2021 Submission Dates Review on ex vivo HSC gene therapy for Nature Rev Genetics Educational Resource: New Horizons in the Management of ADA-SCID Obituary Notice: Professor Shigetaka Asano Online Resource: New Horizons in the Management of ADA-SCID VIVEbiotech makes a capital increase of 3.5 million euros to complete its expansion plan This week in gene and cell therapy - 26 July 2019 This week in gene and cell therapy - 19 July 2019 This week in gene and cell therapy - 12 July 2019 This week in gene and cell therapy - 5 July 2019 This week in gene and cell therapy - 28 June 2019 VIVEbiotech receives an issue notification of the patent grant for the LENTISOMA technology from the United States Patent and Trademark Office This week in gene and cell therapy - 21 June 2019 This week in gene and cell therapy - 7 June 2019 This week in gene and cell therapy - 31 May 2019 This week in gene and cell therapy - 24 May 2019 This week in gene and cell therapy - 17 May 2019 This week in gene and cell therapy - 10 May 2019 This week in gene and cell therapy - 3 May 2019 This week in gene and cell therapy - 26 April 2019 This week in gene and cell therapy - 12 April 2019 This week in gene and cell therapy - 5 April 2019 John Bell and Lisa Riedmayr win inaugural ESGCT PPE Award This week in gene and cell therapy - 8 March 2019 This week in gene and cell therapy - 22 February 2019 This week in gene and cell therapy - 15 February 2019 This week in gene and cell therapy - 1 February 2019 This week in gene and cell therapy - 25 January 2019 This week in gene and cell therapy - 18 January 2019 This week in gene and cell therapy - 4 January 2019 This week in gene and cell therapy - 14 December 2018 This week in gene and cell therapy - 7 December 2018 Consensus statement of European Societies of Gene and Cell Therapy on the reported birth of genome-edited babies in China This week in gene and cell therapy - 23 November 2018 This week in gene and cell therapy - 16 November 2018 This week in gene and cell therapy - 9 November 2018 This week in gene and cell therapy - 2 November 2018 This week in gene and cell therapy - 7 September 2018 This week in gene and cell therapy - 31 August 2018 This week in gene and cell therapy - 24 August 2018 This week in gene and cell therapy - 10 August 2018 This week in gene and cell therapy - 3 August 2018 This week in gene and cell therapy - 20 July 2018 This week in gene and cell therapy - 13 July 2018 This week in gene and cell therapy - 6 July 2018 This week in gene and cell therapy - 22 June 2018 This week in gene and cell therapy - 15 June 2018 This week in gene and cell therapy - 8 June 2018 This week in gene and cell therapy - 1 June 2018 This week in gene and cell therapy - 25 May 2018 This week in gene and cell therapy - 18 May 2018 This week in gene and cell therapy - 4 May 2018 This week in gene and cell therapy - 27 April 2018 This week in gene and cell therapy - 20 April 2018 This week in gene and cell therapy - 6 April 2018 Promising results of stem cell therapy for MS This week in gene and cell therapy - 9 March 2018 This week in gene and cell therapy - 16 February 2018 This week in gene and cell therapy - 9 February 2018 This week in gene and cell therapy - 2 February 2018 This week in gene and cell therapy - 19 January 2018 This week in gene and cell therapy - 12 January 2018 This week in gene and cell therapy - 5 January 2018 2017 breakthroughs in medicine dominated by gene and cell therapy FDA approved Luxturna, a gene therapy product for inherited blindness This week in gene and cell therapy - 8 December 2017 This week in gene and cell therapy - 1 December 2017 This week in gene and cell therapy - 24 November 2017 This week in gene and cell therapy - 3 November 2017 This week in gene and cell therapy - 27 October 2017 New base editor extends machinery to correct single base pair mutations First FDA approval for CAR-T cell therapy First report of JCAR017 trial: CAR-T cell activity observed in the brain Gene addition of micro-dystrophin improves Duchenne muscular dystrophy symptoms in dogs Proof of concept for new strategy of genome editing to correct splice-site mutations Step forward for precision medicine - personalised anti-cancer vaccine tested in patients Genome editing used to treat Huntington's disease in mice Using genome editing to treat chronic inflammation New genome editing resources for patients and families First report from diabetes islet transplantation trial NCT02213003 First clinical trial with in vivo genome editing Phase I trial of gene therapy for age-related macular degeneration completed ESGCT welcomes two Student Board Members Feng Zhang Discusses CRISPR and Future of Gene Editing in Interview in Human Gene Therapy ESGCT would like to express its sadness and dismay at the loss of Dr. Manfred Schmidt. Manfred passed away on 13th January 2022, age 54. We extend our thoughts and condolences to his family, friends and colleagues. Dr. Manfred Schmidt was a pioneer in the gene and cell therapy field, with more than 25 years experience in the sector. He was the Co-Founder and CEO of GeneWerk GmbH, based in Heidelberg, Germany. His most recent academic role was the Section Head of Molecular and Gene Therapy at the German Cancer Research Center, also part of the National Center for Tumor Diseases in Heidelberg, Germany. Manfred obtained his doctoral degree from University of Freiburg, and a Diploma degree in Biology in University Hohenheim, Germany. He authored more than 120 peer-reviewed publications in international high-impact journals.... MORE